| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_df5e3dfa52906aba5e5026c1d7fc3337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6eaaaac903c56d7b0a3de1d047337d3b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5152 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2003-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2012-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e18c57261138ce00e7f8933cd5cf07cf |
| publicationDate |
2012-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8277806-B2 |
| titleOfInvention |
Use of trifunctional bispecific and trispecific antibodies for the treatment of malignant ascites |
| abstract |
The invention describes the use of a pharmaceutical preparation containing a trifunctional bispecific and/or trispecific having the following properties:n a) binding to a T cell; b) binding to at least an antigen on a tumor cell associated with malignant ascites and/or pleural effusion; c) binding, by its Fc portion (in the case of bispecific antibodies) or by a third specificity (in the case of trispecific antibodies), to Fc receptor-positive cells for the destruction of the tumor cells in the treatment of malignant ascites and/or pleural effusion. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8663638-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10633440-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11697684-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010322933-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10071158-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3954703-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10576149-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10647768-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11174315-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015184203-A1 |
| priorityDate |
2000-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |